These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

865 related items for PubMed ID: 18804512

  • 1. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N, Zahedifard F, Azizi H, Taslimi Y, Alonso MJ, Rafati S.
    Vaccine; 2008 Oct 29; 26(46):5822-9. PubMed ID: 18804512
    [Abstract] [Full Text] [Related]

  • 2. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
    Rafati S, Zahedifard F, Azari MK, Taslimi Y, Taheri T.
    Exp Parasitol; 2008 Mar 29; 118(3):393-401. PubMed ID: 18093586
    [Abstract] [Full Text] [Related]

  • 3. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
    Rafati S, Zahedifard F, Nazgouee F.
    Vaccine; 2006 Mar 15; 24(12):2169-75. PubMed ID: 16325969
    [Abstract] [Full Text] [Related]

  • 4. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
    Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S, Rad MA.
    Vaccine; 2005 May 25; 23(28):3716-25. PubMed ID: 15882533
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N, Gholami E, Zahedifard F, Safaee N, Rafati S.
    Exp Parasitol; 2011 Mar 25; 127(3):627-36. PubMed ID: 21187087
    [Abstract] [Full Text] [Related]

  • 6. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S.
    Vaccine; 2004 May 07; 22(15-16):1930-40. PubMed ID: 15121305
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L.
    Vaccine; 2007 May 22; 25(21):4159-69. PubMed ID: 17395340
    [Abstract] [Full Text] [Related]

  • 9. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 10. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S, Carrión J, Anderson C, Alonso C, Sacks D, Soto M.
    Infect Immun; 2005 Sep 22; 73(9):5842-52. PubMed ID: 16113303
    [Abstract] [Full Text] [Related]

  • 11. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA, Alawa J, Doro B, Henriquez FL, Roberts CW, Nok A, Alawa CB, Alsaadi M, Mullen AB, Carter KC.
    Vaccine; 2012 Feb 08; 30(7):1357-63. PubMed ID: 22210224
    [Abstract] [Full Text] [Related]

  • 12. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A, Ojeda A, López-Fuertes L, Timón M, Altet L, Solano-Gallego L, Sánchez-Robert E, Francino O, Alberola J.
    Vaccine; 2007 Nov 14; 25(46):7962-71. PubMed ID: 17942199
    [Abstract] [Full Text] [Related]

  • 13. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
    Ramos I, Alonso A, Peris A, Marcen JM, Abengozar MA, Alcolea PJ, Castillo JA, Larraga V.
    Vaccine; 2009 Nov 12; 27(48):6695-703. PubMed ID: 19747996
    [Abstract] [Full Text] [Related]

  • 14. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N, Zahedifard F, Doroud D, Doustdari F, Vasei M, Papadopoulou B, Rafati S.
    Parasite Immunol; 2013 Dec 12; 35(12):397-408. PubMed ID: 23710803
    [Abstract] [Full Text] [Related]

  • 15. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R, Kaur S.
    Vaccine; 2010 May 21; 28(23):4002-12. PubMed ID: 20093205
    [Abstract] [Full Text] [Related]

  • 16. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, Larraga V.
    Vaccine; 2008 Jan 17; 26(3):333-44. PubMed ID: 18093705
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection.
    Parody N, Soto M, Requena JM, Alonso C.
    Parasite Immunol; 2004 Jan 17; 26(6-7):283-93. PubMed ID: 15541032
    [Abstract] [Full Text] [Related]

  • 18. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S.
    Vaccine; 2009 Dec 10; 28(1):53-62. PubMed ID: 19818721
    [Abstract] [Full Text] [Related]

  • 19. Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.
    Soto M, Corvo L, Garde E, Ramírez L, Iniesta V, Bonay P, Gómez-Nieto C, González VM, Martín ME, Alonso C, Coelho EA, Barral A, Barral-Netto M, Iborra S.
    PLoS Negl Trop Dis; 2015 May 10; 9(5):e0003751. PubMed ID: 25955652
    [Abstract] [Full Text] [Related]

  • 20. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells.
    Carrión J, Folgueira C, Alonso C.
    Vaccine; 2008 May 12; 26(20):2537-44. PubMed ID: 18400342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.